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SuMMAry – Our observational study evaluated current management of elevated low-density 
lipoprotein cholesterol (ldl-C) in adult secondary prevention patients (all very high risk (VHr) by 
european guidelines) attending specialist clinics across Croatia. data were collected retrospectively 
from patient records for the preceding 12 months. The subset judged to be at extreme risk (er; 
American Association of Clinical endocrinologists (AACe) criteria; n=48) were compared with the 
remaining patients (VHr group; n=41). All patients were receiving statins (75.6% VHr/81.3% er at 
high-intensity), with only a minority receiving concomitant lipid-lowering treatment (7.3% 
VHr/16.7% er). Median (Q1, Q3) ldl-C levels at the last visit were 1.9 (1.6, 2.4) mmol/l for 
VHr and 2.1 (1.5, 3.1) mmol/l for er, with only 41.5% (95% Ci 26.3-57.9) of VHr patients and 
27.1% (15.3-41.9) of er patients attaining their ldl-C targets (<1.8 mmol/l and <1.42 mmol/l, 
respectively). Thus, we found that a substantial proportion of VHr and er secondary prevention 
patients being treated across Croatia had ldl-C levels exceeding the targets recommended in the 
european and newer AACe guidelines, but not all were receiving high-intensity statins. identifica-
tion of er patients and their lipid patterns may help optimize usage of high-intensity statin treat-
ment, alone or along with newer treatments, for better control of elevated ldl-C.
key words: Hyperlipidemia; Secondary prevention; High-risk patients; Very high-risk patients; Ex-
treme risk patients
Correspondence to: Hrvoje Pintarić, MD, PhD, School of dental 
Medicine, university of Zagreb, gundulićeva 5, Hr-10000 Za-
greb, Croatia
e-mail: pintaric.hrvoje@gmail.com
received October 1, 2019, accepted August 28, 2020
Introduction
dyslipidemia is a primary major risk factor for 
 atherosclerotic cardiovascular disease (ASCVd), the 
leading cause of death and disability in the developed 
world1. lipid-lowering therapy (llt) aimed at reduc-
ing elevated low-density lipoprotein cholesterol 
(ldl-C), the dominant form of atherogenic choles-
terol, substantially reduces the risk of cardiovascular 
(CV) events in the primary and secondary prevention 
settings2-4. Statin drugs have provided the backbone of 
llt for several decades.
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given that the degree of risk reduction is propor-
tional to the magnitude of ldl-C reduction5, the eu-
ropean Society of Cardiology/european Atheroscle-
rosis Society (eSC/eAS)6,7 have set specific ldl-C 
targets for patients with hyperlipidemia, according to 
their CV risk. in 2011, an ldl-C target of <2.5 
mmol/l was recommended for high risk (Hr) and 
<1.8 mmol/l for very high risk (VHr) patients6, with 
the Hr goal being subsequently revised to <2.6 
mmol/l in 20167. More recently, a new risk category, 
extreme risk (er), has been defined in guidelines from 
the American Association of Clinical endocrinolo-
gists (AACe) and American College of endocrinol-
ogy (ACe) as “progressive atherosclerotic cardiovascu-
lar disease (ASCVd) after achieving ldl-C <1.8 
mmol/l; established clinical CV disease in patients 
with diabetes mellitus, chronic kidney disease (Ckd) 
stage 3/4, or heterozygous familial hypercholesterol-
emia (fH); history of premature ASCVd (male aged 
<55 years and female aged <65 years)”8. individuals 
falling into this category have a significantly increased 
risk of a major or fatal ASCVd event over the next 
4-5 years. An ldl-C target of <1.42 mmol/l has 
been advocated for such patients8, on the basis of find-
ings from large studies such as iMPrOVe-it (exam-
ining outcomes in subjects with acute coronary syn-
drome: Vytorin vs. simvastatin)9 and fOurier (fur-
ther cardiovascular outcomes research with PCSk9 
inhibition in subjects with elevated risk)10, showing 
that lowering ldl-C to the levels below previous tar-
gets provided additional outcome benefits.
data from observational studies and surveys in 
Western europe and the uS indicate that ldl-C tar-
gets are not being met in a substantial proportion of 
patients treated for dyslipidemia11,12. A retrospective/
prospective observational study was conducted to ex-
plore the management of dyslipidemia across several 
Central/eastern european countries and israel, with a 
focus on treatment patterns and ldl-C target 
achievements13. Here we present results for the Croa-
tian subpopulation.
Patients and Methods
briefly, this regional study was a retrospective/pro-
spective non-interventional, observational study that 
enrolled adult patients diagnosed with hyperlipidemia 
who were receiving llt and attending a specialist 
(cardiologist, diabetologist) and/or internist for rou-
tine visit13. Patients receiving llt in the course of an 
interventional clinical trial were excluded. data were 
collected from individual patient medical records for 
12 months prior to enrolment (retrospective phase; all 
countries) and up to 6 months following enrolment 
(prospective phase; in romania, Poland and the Czech 
republic only). Patients were required to have at least 
2 ldl-C values and valid llt documentation (type 
of medication and dose) for the retrospective data col-
lection period and provided informed consent where 
required by local regulations.
Our Croatian centers enrolled only VHr patients, 
classified according to the european guidelines6. indi-
viduals who fulfilled the criteria for the newly defined 
er category proposed by AACe/ACe8 were identi-
fied and their data compared with the remaining pa-
tients (designated as the VHr group).
Objectives
The primary study objective was to estimate the 
proportion of patients achieving recommended 
ldl-C target levels of <1.8 mmol/l for VHr6 and 
<1.42 mmol/l for er8. Secondary objectives included 
ldl-C levels over time; use of statins and other llt 
(type, dose, frequency) over time; CV events; clinical 
characteristics (demographics, medical history includ-
ing CV events, symptoms of statin intolerance, hospi-
talizations); and parameters of clinical management of 
patients. no formal hypothesis was tested.
Study sample size
it was planned to enroll a total of 80-150 subjects per 
country in the regional study, based on the projected 
50% of subjects achieving the primary outcome measure 
(achievement of eSC/eAS ldl-C targets). Thus, a 
sample size of 80 patients would enable the percentage 
to be estimated with 95% confidence interval (Ci) with 
a half-width of 11.0%, with a corresponding half-width 
of 8.0% for a sample size of 150 patients.
Data analysis
Summary statistics only are presented for categori-
cal variables (frequency and percentage in category, 
with 95% Ci) and continuous variables (number of 
subjects, mean, median, standard deviation or standard 
error, interquartile range, minimum, and maximum). 
There was no data imputation.
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Results
Study population
A total of 89 patients, mean age 65.1 (range 46-82) 
years, were enrolled between december 2016 and 
March 2017 at four different sites. All were secondary 
prevention patients, including 30 patients with con-
comitant diabetes and 25 patients with St-segment 
elevation myocardial infarction. There were no fH pa-
tients. forty-eight patients met the criteria for er8, 
leaving 41 patients in the VHr group. Patient charac-
teristics are summarized in table 1, while lifestyle risk 
factors are listed in table 2. CV events (n=1-7) were 
recorded in 72 (80.9%) patients, including 33 (80.5%) 
VHr and 39 (81.3%) er patients during the observa-
tion period. during this period, 77 (86.5%) patients 
were hospitalized, including 35 (85.4%) VHr and 42 
(87.5 %) er patients, most commonly because of 
myocardial infarction (n=18; 20.2%) or coronary re-
vascularization (n=14; 15.7%).
Lipid-lowering therapies
All patients were receiving statins, mostly as mono-
therapy (VHr 92.7%/er 83.3%), with very few receiv-
ing concomitant llt (fibrates: VHr 4.9%/er 14.6% 
Table 1. Study population (N=89)
Characteristic
Patients, n (%)




Male/female 35 (85.4%) /6 (14.6%)
34 (70.8%) 
/14 (29.2%)
Age (yrs), mean (range) 66.1 (56-78) 64.3 (46-82)






Current smoker 9 (22.0%) 10 (20.8%)
diabetes 6 (14.6%) 24 (50.0%)
SteMi 12 (29.3%) 13 (27.1%)
Statin-intoleranta 1 (2.4%) 2 (4.2%)
time from diagnosisb
 <1 year 9 (22.0%) 13 (27.1%)
 ≥1 to <2 years 2 (4.9%) 2 (4.2%)
 ≥2 to <3 years 1 (2.4%) 1 (2.1%)
 ≥3 to <4 years 0 (0%) 1 (2.1%)
 ≥4 to <5 years 1 (2.4%) 1 (2.1%)
 ≥5 years 8 (19.5%) 12 (25.0%)
 unknown 20 (48.8%) 18 (37.5%)
SteMi = St-elevation myocardial infarction; asymptoms of statin 
intolerance; btime elapsed from diagnosis of hyperlipidemia to 
study enrolment.
Table 2. Lifestyle factors in study population
Parameter Category
Patients, n (%)
All (n=89) Very high risk (n=41)
extreme risk 
(n=48)
former smoker yes 28 (31.5%) 12 (29.3%) 16 (33.3%)
no 26 (29.2%) 11 (26.8%) 15 (31.3%)
unknown 35 (39.3%) 18 (43.9%) 17 (35.4%)
Current smoker yes 19 (21.3%) 9 (22.0%) 10 (20.8%)
no 70 (78.7%) 32 (78.0%) 38 (79.2%)
Alcohol ≥3 units/day no 41 (100.0%) 48 (100.0%)
low calorie diet yes 41 (46.1%) 19 (46.3%) 22 (45.8%)
no 33 (37.1%) 15 (36.6%) 18 (37.5%)
unknown 15 (16.9%) 7 (17.1%) 8 (16.7%)
low cholesterol diet yes 26 (63.4%) 32 (66.7%)
no 8 (19.5%) 8 (16.7%)
unknown 7 (17.1%) 8 (16.7%)
Physical activity little/none 56 (62.9%) 27 (65.9%) 29 (60.4%)
light (1-3 days/week) 19 (21.3%) 6 (14.6%) 13 (27.1%)
Moderate (3-5 days/week) 13 (14.6%) 7 (17.1%) 6 (12.5%)
Very active (6-7 days/week) 1 (1.1%) 1 (2.4%) 0 (0%)
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Statin 38 (92.7%) 40 (83.3%)
Statin + ezetimibe 1 (2.4%) 1 (2.1%)
Statin + fibrates** 2 (4.9%) 7 (14.6%)
total 41 (100%) 48 (100%)
*Anytime during the observation period. each subject is included 
only once (e.g., if they received statin monotherapy for part of the 
observation period and statin + ezetimibe for another part, they are 
included under statin + ezetimibe); **fenofibrate or gemfibrozil.
Table 4. Summary of statin use by type and dose*
type dose (mg) Very high risk, n (%) extreme risk, n (%)
first visit last visit first visit last visit
10 1 (2.18%) 1 (2.18%)
Atorvastatin 20 1 (2.4%) 3 (7.3%) 3 (6.3%) 2 (4.2%)
40 5 (12.2%) 7 (17.1%) 5 (10.4%) 6 (12.5%)
80 0 (0%) 8 (19.5%) 3 (6.3%) 7 (14.6%)
fluvastatin 40 1 (2.4%) 0 (0%) 0 (0%) 0 (0%)
80 1 (2.4%) 0 (0%) 0 (0%) 0 (0%)
rosuvastatin 10 1 (2.4%) 0 (0%) 1 (2.1%) 3 (6.3%)
20 3 (7.3%) 0 (0%) 4 (8.3%) 3 (6.3%)
40 2 (4.9%) 2 (4.9%) 1 (2.1%) 0 (0%)
Simvastatin 10 1 (2.4%) 0 (0%) 0 (0%) 0 (0%)
20 1 (2.4%) 0 (0%) 0 (0%) 0 (0%)
*data were missing from analysis for approximately 50% of patients. Patients may have been taking >1 statin. Separate analysis showed that 
31 (75.6%) very high risk patients and 39 (81.3%) extreme risk patients were taking high-intensity statins (atorvastatin 40-80 mg or rosu-
vastatin 20-40 mg/day) at some point during the study.
Table 5. Most common reasons for switching/changing/
discontinuing lipid-lowering therapy (LLT)
Status and reason*
Patients, n (%)




Switched to other  
llt (including statins) 6 (14.6%) 7 (14.6%)
insufficient lipid 
-lowering effect 3 (50.0%) 3 (42.9%)
Modified dose  
and/or frequency 5 (12.2%)  8 (16.7%)
insufficient lipid 
-lowering effect 3 (60.0%)  3 (37.5%)
discontinued 0 (0%) 4 (8.3%)
*reasons expressed as % of status total; all reasons with >1 patient 
are shown.
or ezetimibe: VHr 2.4%/er 2.1%) (table 3); 75.6% of 
VHr and 81.3% of er patients were taking high-inten-
sity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 
mg/day) at some point during observation (table 4).
Thirteen patients (14.6%: 6 VHr/7 er) had a 
switch in llt during observation and another 13 pa-
tients (14.6%; 5 VHr/8 er) had modifications in dose 
and/or frequency, mostly because of insufficient lipid-
lowering effect, as shown in table 5. four patients (all 
er) discontinued their llt for various reasons.
LDL-C and other lipid parameters
As shown in figure 1, median (Q1, Q3) ldl-C 
levels were 2.5 (2.0, 3.8) mmol/l at the first and 1.9 
(1.6, 2.4) mmol/l at the last visit of observation for 
VHr. The respective levels were 2.4 (1.7, 3.7) mmol/l 
and 2.0 (1.5, 3.1) mmol/l for er. detailed ldl-C 
and other lipid data (total and Hdl-cholesterol and 
triglycerides) are shown in table 6.
during observation, only 17 (41.5%; 95% Ci 
26.32-57.89) VHr patients and 13 (27.1%; 15.28-
41.85) er patients were found to have ldl-C levels 
within the target ones (<1.8 mmol/l and <1.42 
mmol/l, respectively) (fig. 2).
Median ldl-C, total and Hdl-cholesterol at the 
last visit were compared between VHr and er pa-
tients in post-hoc analysis. Only Hdl-C showed a 
(marginally) significant difference between the two 
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Table 6. Lipid levels (mmol/L) at first and last visit of the observation period
Parameter Visit Very high risk extreme risk
ldl-C first n 41 48
Median 2.510 2.350
25th percentile (Q1) 1.980 1.705
75th percentile (Q3) 3.800 3.715
Min 1.3 0.7
Max 6.9 5.8
last n 41 48
Median 1.900 2.030
25th percentile (Q1) 1.600 1.530
75th percentile (Q3) 2.400 3.070
Min 0.8 0.52
Max 4.4 4.6




25th percentile (Q1) 1.000 0.815
75th percentile (Q3) 1.400 1.380
Min 0.70 0.50
Max 2.20 1.70




25th percentile (Q1) 1.000 0.800
75th percentile (Q3) 1.300 1.200
Min  0.60 0.50
Max 2.17 1.80




25th percentile (Q1) 3.600 3.400
75th percentile (Q3) 5.850 5.500
Min 3.00 2.30
Max 9.00 8.40




25th percentile (Q1) 3.200 3.300
75th percentile (Q3) 3.900 4.800
Min 2.10 1.70
Max 6.30 7.10




25th percentile (Q1) 1.300 1.200







25th percentile (Q1) 1.100 1.000
75th percentile (Q3) 1.500 2.400
Min 0.50 0.40
Max 4.40 4.30
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Fig. 1. Median LDL-C levels (mmol/L) at first and last 
visit of the observation period according to cardiovascular 
risk category (bars indicate Q1 and Q3).
Fig. 2. Achievement of ESC/EAS and AACE-defined 
LDL-C targets by cardiovascular risk category at any 
time during the observation period. Results shown as 
percentage of patients in category with two-sided 95% 
confidence intervals in brackets.












































*extreme risk vs. very high risk.
subgroups (1.1 in VHr vs. 1.0 mmol/l in er; 
p=0.051) (table 7).
Adverse events
Only three (<1%) patients were listed as having 
symptoms of statin intolerance (statin-associated 
muscle symptoms (SAMS) or hepatotoxicity).
Discussion
This observational study explored patterns of 
 management and ldl-C target achievement in VHr 
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secondary prevention patients with dyslipidemia in 
Croatia.
Although all patients were receiving statins, mostly 
at high intensity (75.6% VHr/81.3% er), only a mi-
nority were receiving concomitant llt (7.3% 
VHr/16.7% er; either ezetimibe or fenofibrate/gem-
fibrozil). The most common reason for discontinuing 
or changing llt during observation was insufficient 
lipid-lowering effect. Overall, less than half of our pa-
tients (n=42, 47.2%; 95% Ci 36.5-58.1%) were found 
to have ldl-C levels <1.8 mmol/l during observa-
tion. These proportions were slightly better than those 
from the main regional study13, in which 42.0% 
(39.1%-45.0%) of VHr patients achieved <1.8 
mmol/l. However, our study population differed from 
the main regional study in that we did not include any 
fH patients. Approximately half of our patients met 
the criteria for er8 and less than 30% of this subgroup 
met their very stringent target of <1.42 mmol/l. it 
seems likely that such a category will be included in 
future eSC guidelines.
underdosing and statin discontinuation/poor ad-
herence to therapy, which can be a consequence of 
statin intolerance, are recognized as the key contribu-
tors to inadequate ldl-C reduction in patients with 
dyslipidemia and have been linked to poorer clinical 
outcomes7,14. detailed expert guidelines for diagnosis 
and management of SAMS are now available and it is 
hoped that improving awareness of these issues among 
physicians and patients will have a beneficial effect on 
statin adherence15. Other potential reasons for failure 
to reach ldl-C targets include reimbursement/fi-
nancial issues leading to suboptimal treatment, and 
extremely high baseline ldl-C levels.
The approval in 2015 of the proprotein convertase 
subtilisin-kexin type 9 inhibitors (PCSk9i) evolocum-
ab and alirocumab, which improve ldl-receptor 
(ldlr) recycling and increase ldlr availability on 
hepatocyte cell surfaces16, has provided new options 
for treatment of dyslipidemia. Adding PCSk9i can 
lower ldl-C by additional 60% in patients who are 
already receiving maximal statin therapy10,17-20, and 
outcome data have shown that this translates into a 
significantly reduced risk of CV events10,21. to date, 
PCSk9i have been well tolerated, with few patients 
discontinuing treatment due to adverse events10,18,20. 
european guidelines recommend that PCSk9i may be 
considered for VHr patients with ASCVd, including 
those with progressive ASCVd or diabetes with target 
organ damage or a major CV risk factor or severe fH 
without ASCVd but severely elevated ldl-C de-
spite maximal statin/ezetimibe therapy22. none of our 
Croatian patients were receiving these agents.
limitations of our observational study included 
small size of some subgroups, such as the statin intol-
erance group. Changes in ldl-C levels should be in-
terpreted with caution, given the variable duration of 
llt, as well as the lack of predefined timepoints for 
ldl-C measurements. There also were some missing 
data, e.g., on lifestyle risk factors.
Conclusions
Our findings indicate that a substantial proportion 
of VHr and er secondary prevention patients being 
treated across Croatia have ldl-C levels exceeding 
the targets recommended in european and newer 
AACe/ACe guidelines. despite this, not all patients 
are receiving high-intensity statins as recommended. 
identification of er patients and their lipid patterns 
may help optimize the usage of high-intensity statin 
treatment, alone or in combination with newer treat-
ments, for better control of elevated ldl-C.
data availability. The datasets used and/or analyzed 
during the study are available from the corresponding 
author on reasonable request. Qualified researchers 
may request data from Amgen clinical studies. Com-
plete details are available at: http://www.amgen.com/
datasharing.
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Sažetak
liJeČenJe HiPerliPideMiJe u bOleSnikA  
S VrlO ViSOkiM i ekStreMnO ViSOkiM riZikOM u HrVAtSkOJ
H. Pintarić, M. Knezović Florijan, I. Bridges, R. Steiner, L. Zaputović i D. Miličić
Ova opservacijska studija analizirala je trenutno liječenje povišenih vrijednosti ldl kolesterola (ldl-C) u bolesnika 
koji su liječeni zbog hiperlipidemije u okviru sekundarne prevencije (prema europskim smjernicama svi su pripadali u skupi-
nu bolesnika s vrlo visokim rizikom) i kontrolirali su se kod specijalista diljem Hrvatske. Podaci su prikupljeni retrospektivno 
tijekom 12 mjeseci iz bolesničke medicinske dokumentacije. Skupina bolesnika za koju je procijenjeno da je u eks tremno 
visokom riziku (er; AACe kriteriji; n=48) uspoređivana je sa skupinom s visokim rizikom (VHr skupina; n=41). Svi bole-
snici su primali statine (75,6% bolesnika s VHr/81,3% bolesnika s er liječeno je visokim dozama statina), dok je manjina 
bolesnika istodobno primala i drugu terapiju za snižavanje lipida (7,3% VHr/er 16,7%). kod posljednjeg posjeta medijan 
vrijednosti ldl-C (Q1, Q3) u skupini VHr iznosio je 1,9 (1,6, 2,4) mmol/l, dok je u skupini er iznosio 2,1 (1,5, 3,1) 
mmol/l. Samo 41,5% (95% Ci 26,3-57,9) bolesnika s VHr i 27,1% (15,3-41,9) bolesnika s er imali su razine ldl-C 
unutar ciljne razine (<1,8 mmol/l i <1,42 mmol l). rezultati studije pokazuju kako unatoč mjerama sekundarne prevencije 
velik broj visokorizičnih bolesnika i bolesnika s ekstremnim rizikom ima razine ldl-C koje premašuju ciljne vrijednosti 
preporučene u europskim i novijim AACe smjernicama, ali usprkos navedenom mnogi bolesnici nisu liječeni statinima u 
visokoj dozi. identifikacija bolesnika s ekstremnim rizikom i njihovih lipidnih obrazaca mogla bi povećati upotrebu visokih 
doza statina, samostalno ili u kombinaciji s novijim lijekovima, radi bolje kontrole povišenog ldl-C
ključne riječi: Hiperlipidemija; Sekundarna prevencija; Bolesnici s visokim rizikom; Bolesnici s vrlo visokim rizikom; Bolesnici 
s ekstremno visokim rizikom
